ReviewFrontiers in microbiology2022
The research progress in the interaction between
Review in Frontiers in microbiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Worldwide trend in research onFrontiers in microbiology · 2024Pooled it
- Oral Mycobiome: Composition, Functionality and Clinical Implication.Journal of fungi (Basel, Switzerland) · 2026Review
- Review
- Contribution of fungal diseases to the U.S. chronic disease burden.Clinical microbiology reviews · 2026Review
- The trio of Candida albicans, immune cells, and cancer progression: a complex interplay driving tumorigenesis.Medical oncology (Northwood, London, England) · 2025Review
- The multi-kingdom cancer microbiome.Nature microbiology · 2025Review
- Head and Neck Malignancies in Autoimmune Polyendocrine Syndrome Type 1 (APS-1/APECED): A Scoping Review of Molecular Pathogenesis, Clinical Features, and Outcomes.International journal of molecular sciences · 2025Article
- Role ofCancer pathogenesis and therapy · 2025Review
- The application of organoids in investigating immune evasion in the microenvironment of gastric cancer and screening novel drug candidates.Molecular cancer · 2025Review
- Small Intestinal Bacterial and Fungal Overgrowth: Health Implications and Management Perspectives.Nutrients · 2025Review
- Multidrug-ResistantThe Malaysian journal of medical sciences : MJMS · 2025Review
- The power of microbes: the key role of gut microbiota in the initiation and progression of colorectal cancer.Frontiers in oncology · 2025Review
- Evaluating the Role ofInterdisciplinary perspectives on infectious diseases · 2025Review
- Oral Microbial Changes in Oral Squamous Cell Carcinoma: Focus onMedicina (Kaunas, Lithuania) · 2024Article
- Article
- Enhancing immunity againstmBio · 2024Article
- Diagnostic and prognostic values of NSCLC patients with or without obstructive pneumonia after sleeve lobectomy.Frontiers in cellular and infection microbiology · 2024Article
- Oral microbiota and oral squamous cell carcinoma: a review of their relation and carcinogenic mechanisms.Frontiers in oncology · 2024Review
- Candidiasis in breast cancer: Tumor progression or not?Iranian journal of basic medical sciences · 2024Review
- Yeast species in the respiratory samples of COVID-19 patients; molecular tracking ofFrontiers in cellular and infection microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.